Relevant Literature: Multiple Myeloma

Slides

Mayo Clinic Myeloma Group: Membership, Strengths, and Achievements
Mass spectrometric detection of Monoclonal Proteins
Active Drugs in Myeloma and Mechanism of Action
How I Treat Myeloma 2020

Update on Newly Diagnosed Myeloma

Reference Articles

IMWG Diagnostic Criteria for Myeloma and Related Disorders
IMWG Response Criteria and MRD Criteria
Smoldering Multiple Myeloma

2022 Update on Diagnosis and Treatment of Myeloma

Current Treatment Algorithms for Newly diagnosed and Relapsed Myeloma

Current Treatment Algorithm for Smoldering Multiple Myeloma

Trial Publications

Phase III Trials
ASPIRE Trial
ECOG E4A03 Trial
Thalidomide ECOG E1A00 Trial
Thalidomide Smoldering MM Trial

ENDURANCE TRIAL VRd vs KRd

Lenalidomide Smoldering MM Trial

BELLINI Venetoclax Trial

Phase II Trials
EVOLUTION Trial
Pomalidomide Trial
CYKLONE Trial
Ixazomib Trial
Dinaciclib Trial

Retrospective studies

Ho M et al. The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). BCJ 2021

Kaddoura M et al Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood advances 2021

Visram A et al. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia 2021.

Abdallah N et al. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. CCR 2020

Abdallah N et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances 2020

Al-Saleh AS et al. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma Myeloma and Leukemia 2020

Gonsalves WI et al. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. AJH 2020

Lakshman A et al. Natural history of multiple myeloma with de novo del(17p). Leukemia 2017

Muchtar E et al. Autologous stem cell transplant for multiple myeloma patients 70 years or older. BMT 2016

Chakraborty R et al. Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. Leukemia & Lymphoma 2016

Binder M et al. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. AJH 2015

HIGHLY CITED LIST

Myeloma Investigators in Top Cited Authors